The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI.
G. R. Oxnard
No relevant relationships to disclose
Y. Y. Janjigian
No relevant relationships to disclose
M. E. Arcila
No relevant relationships to disclose
M. G. Kris
Consultant or Advisory Role - Boehringer Ingelheim; Pfizer
M. Ladanyi
No relevant relationships to disclose
C. G. Azzoli
Research Funding - Genentech
V. A. Miller
Consultant or Advisory Role - Boehringer Ingelheim; Genentech; OSI Pharmaceuticals; Pfizer; Roche